Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

被引：11
|
作者：
Hamilton, E. P. [1 ]
Barve, M. A. [2 ]
Tolcher, A. W. [3 ]
Buscema, J. [4 ]
Papadopoulos, K. P. [5 ]
Zarwan, C. [6 ]
Anderson, C. K. [7 ]
Doroshow, D. [8 ]
Wang, D. [9 ]
Huebner, D. [10 ]
Jansen, V. M. [10 ]
Jarlenski, D. [10 ]
Mosher, R. [10 ]
Kaufman, J. [10 ]
Moore, K. N. [11 ]
Richardson, D. L. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[2] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[3] NEXT OncologyTM, San Antonio, TX USA
[4] Arizona Oncol Associates, Oncol, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut START, Clin Res, San Antonio, TX USA
[6] Lahey Hosp & Med Ctr, Oncol, Burlington, MA USA
[7] Willamette Valley Canc Inst, Oncol, Eugene, OR USA
[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Hematol Oncol, New York, NY 10029 USA
[9] Henry Ford Hosp, Hematol Oncol, Detroit, MI 48202 USA
[10] Mersana Therapeut Inc, Clin Dev, Cambridge, MA USA
[11] Univ Oklahoma, Sarah Cannon Res Inst, Stephenson Canc Ctr, Gynecol Oncol Dept, Oklahoma City, OK USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
836P
引用
收藏
页码：S627 / S628
页数：2
相关论文
共 50 条
  • [21] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
    Gerber, David E.
    Infante, Jeffrey R.
    Gordon, Michael S.
    Goldberg, Sarah B.
    Martin, Miguel
    Felip, Enriqueta
    Martinez Garcia, Maria
    Schiller, Joan H.
    Spigel, David R.
    Cordova, Julie
    Westcott, Valerie
    Wang, Yulei
    Shames, David S.
    Choi, YounJeong
    Kahn, Robert
    Dere, Randall C.
    Samineni, Divya
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Royer-Joo, Stephanie
    Lemahieu, Vanessa
    Schuth, Eva
    Vaze, Anjali
    Maslyar, Daniel
    Humke, Eric W.
    Burris, Howard A., III
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 364 - 372
  • [23] Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
    Suzanne Trudel
    Nikoletta Lendvai
    Rakesh Popat
    Peter M. Voorhees
    Brandi Reeves
    Edward N. Libby
    Paul G. Richardson
    Axel Hoos
    Ira Gupta
    Veronique Bragulat
    Zangdong He
    Joanna B. Opalinska
    Adam D. Cohen
    Blood Cancer Journal, 9
  • [24] Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
    Liu, J. F.
    Moore, K. N.
    Birrer, M. J.
    Berlin, S.
    Matulonis, U. A.
    Infante, J. R.
    Wolpin, B.
    Poon, K. A.
    Firestein, R.
    Xu, J.
    Kahn, R.
    Wang, Y.
    Wood, K.
    Darbonne, W. C.
    Lackner, M. R.
    Kelley, S. K.
    Lu, X.
    Choi, Y. J.
    Maslyar, D.
    Humke, E. W.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2124 - 2130
  • [25] Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.
    Liu, Joyce
    Moore, Kathleen
    Birrer, Michael
    Berlin, Suzanne
    Matulonis, Ursula
    Infante, Jeffrey
    Xi, Jian
    Kahn, Robert
    Wang, Yulei
    Wood, Katie
    Coleman, Daniel
    Maslyar, Daniel
    Humke, Eric
    Burris, Howard
    CANCER RESEARCH, 2013, 73 (08)
  • [26] UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
    Richardson, Debra
    Iyer, Gopa
    Schmid, Anita
    Palma, Norma
    Navarro, Willis
    Ahnert, Jordi Rodon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S285 - S286
  • [27] Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
    Moore, Kathleen N.
    Martin, Lainie P.
    O'Malley, David M.
    Matulonis, Ursula A.
    Konner, Jason A.
    Perez, Raymond P.
    Bauer, Todd M.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1112 - +
  • [28] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
    Gordon, Michael S.
    Gerber, David E.
    Infante, Jeffrey R.
    Xu, Jian
    Shames, David S.
    Choi, Younjeong
    Kahn, Robert S.
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel J.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
    Banerjee, S.
    Oza, A. M.
    Birrer, M. J.
    Hamilton, E. P.
    Hasan, J.
    Leary, A.
    Moore, K. N.
    Mackowiak-Matejczyk, B.
    Pikiel, J.
    Ray-Coquard, I.
    Trask, P.
    Lin, K.
    Schuth, E.
    Vaze, A.
    Choi, Y.
    Marsters, J. C.
    Maslyar, D. J.
    Lemahieu, V.
    Wang, Y.
    Humke, E. W.
    Liu, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 917 - 923
  • [30] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
    Martin, Lainie P.
    Konner, Jason A.
    Moore, Kathleen N.
    Seward, Shelly M.
    Matulonis, Ursula A.
    Perez, Raymond P.
    Su, Ying
    Berkenblit, Anna
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 402 - 407
12345